INVESTABOT
Equity Research
XNYS · PHARMACEUTICAL PREPARATIONS
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
TL;DR: Zoetis grew Q1 2026 revenue 2.9% to $2.26B from $2.20B a year ago, while net income came in at $601 million, or $1.42 per diluted share.
open-market Form 4 only - grants, exercises, tax withholding excluded
0 buyers - 0 unique sellers · 10 accumulating - 4 trimming - 0 unchanged
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| September 17, 2026 | Stetter Mark | — | GRANT | 342.37 | $73 | ~$25K |
| August 31, 2026 | Saccaro James | EVP, CFO & COO | GRANT | 81,063 | — | — |
| August 7, 2026 | Damelio Frank A | — | GIFT | -6,650 | — | — |
| July 10, 2026 | Sarbaugh Keith | Executive Vice President | GRANT | 259.64 | $26 | ~$7K |
| July 10, 2026 | Peck Kristin C | Chief Executive Officer | GRANT | 616.09 | $26 | ~$16K |
| July 10, 2026 | Nayak Abhay U | Executive Vice President | GRANT | 214.62 | $26 | ~$6K |
| July 10, 2026 | Esch Kevin | Executive Vice President | GRANT | 308.05 | $26 | ~$8K |
| July 10, 2026 | Driscoll Rimma | Executive Vice President | GRANT | 237.64 | $26 | ~$6K |
| July 10, 2026 | Fuller Julie | Executive Vice President | GRANT | 314.65 | $26 | ~$8K |
| July 10, 2026 | Lagano Roxanne | Executive Vice President | GRANT | 314.65 | $26 | ~$8K |
| July 10, 2026 | Ferran Astorga Jeannette | Executive Vice President | GRANT | 45.33 | $26 | ~$1K |
| July 10, 2026 | Joseph Wetteny | Chief Financial Officer | GRANT | 363.05 | $26 | ~$10K |
| June 18, 2026 | Stetter Mark | — | GRANT | 317.62 | $79 | ~$25K |
| June 10, 2026 | Mccallister Michael B | — | GIFT | -1,209 | — | — |
| May 21, 2026 | Stetter Mark | — | OPTION_EXERCISE | 1,572 | — | — |
| May 21, 2026 | Stetter Mark | — | OPTION_EXERCISE | -1,572.06 | — | — |
| May 20, 2026 | Parent Louise M | — | OPTION_EXERCISE | 1,944 | — | — |
| May 20, 2026 | Parent Louise M | — | OPTION_EXERCISE | 10,186 | — | — |
| May 20, 2026 | Parent Louise M | — | OPTION_EXERCISE | -1,944.36 | — | — |
| May 20, 2026 | Parent Louise M | — | OPTION_EXERCISE | -10,186.67 | — | — |
| Institution | Shares | Value ($) | Change % | Filing date |
|---|---|---|---|---|
| BlackRock | 36,835,040 | ~$6.4B | — | August 13, 2024 |
| Vanguard Group | 47,780,974 | ~$6.0B | — | January 29, 2026 |
| BlackRock | 37,350,823 | ~$4.7B | — | February 12, 2026 |
| BlackRock | 35,584,312 | ~$4.2B | -4.7% | May 13, 2026 |
| BlackRock | 39,430,181 | ~$2.8B | 10.8% | August 7, 2026 |
| State Street | 19,796,891 | ~$2.5B | — | February 13, 2026 |
| State Street | 19,324,401 | ~$2.3B | -2.4% | May 15, 2026 |
| Morgan Stanley | 15,465,506 | ~$1.9B | — | May 27, 2026 |
| Morgan Stanley | 14,145,735 | ~$1.7B | -8.5% | May 15, 2026 |
| State Street | 19,667,723 | ~$1.4B | 1.8% | August 7, 2026 |
| Morgan Stanley | 8,878,849 | ~$638.0M | -37.2% | August 13, 2026 |
| Goldman Sachs | 3,863,885 | ~$456.7M | 8.1% | May 15, 2026 |
| Goldman Sachs | 3,574,124 | ~$449.7M | — | March 25, 2026 |
| JP Morgan Chase | 3,407,174 | ~$396.4M | 41.9% | May 13, 2026 |
| Citadel Advisors | 5,210,963 | ~$374.5M | 427.3% | August 14, 2026 |
| JP Morgan Chase | 2,401,497 | ~$302.2M | — | February 11, 2026 |
| Goldman Sachs | 3,736,099 | ~$268.5M | -3.3% | August 14, 2026 |
| Millennium Management | 1,801,255 | ~$212.9M | 329.6% | May 15, 2026 |
| Citadel Advisors | 1,622,005 | ~$204.1M | — | February 17, 2026 |
| JP Morgan Chase | 2,630,925 | ~$192.7M | -22.8% | August 12, 2026 |